Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,829.73
-1.9733-0.11%
Number of Gainers:8
Number of Losers:10
Number of Flat:1
PE:- -
High:1,847.82
Open:1,834.63
Low:1,827.63
Close:1,831.70
Volume:80.77M
Turnover:6.14B
Market Cap:1.49T
Float Cap:1.45T

Loading ...

Analyst Warns of Significant Clinical and Regulatory Risks Facing Ibio Inc’s Drug Pipeline

TIPRANKS
·
Aug 31

CanSino Leads HK-Listed Vaccine Makers Lower as BioNTech Halts mRNA Trial

Reuters
·
Aug 31

August Turmoil: Bessent's Intervention and the Quiet Reveal of Policy's Hidden Hand

Deep News
·
Aug 30

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

TIPRANKS
·
Aug 29

BioNTech SE Slides as Bold HIV Bet Takes Shape

TIPRANKS
·
Aug 29

Abbott, Vistra, Unity, United, Nu: Insider Shockwave

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 29

US Stocks Weekly: AI Refuel

Reuters
·
Aug 29

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?

TradingKey
·
Aug 29

Does Peer-Reviewed Phase 1 Soquelitinib Data Reshape The Bull Case For Corvus Pharmaceuticals (CRVS)?

Simply Wall St.
·
Aug 29

BioNTech Stock Falls on Cancer Vaccine Setback Days After Moderna's Big Win

Dow Jones
·
Aug 29

Pfizer EVP Cecile Guegan Files Initial Beneficial Ownership Statement

Reuters
·
Aug 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 29

BioNTech on Track for Worst Day Since March After Ending Colorectal Cancer Trial

Reuters
·
Aug 29

Pfizer Extends Tucatinib Access With New Continuation Study: What Investors Should Know

TIPRANKS
·
Aug 29

Pfizer Expands Autoimmune Pipeline With New Early-Stage Trial of PF-08154225

TIPRANKS
·
Aug 29

Pfizer Targets China’s Obesity Market With New Phase 3 Berobenatide Trial

TIPRANKS
·
Aug 29